1. Home
  2. PBH vs MESO Comparison

PBH vs MESO Comparison

Compare PBH & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prestige Consumer Healthcare Inc.

PBH

Prestige Consumer Healthcare Inc.

HOLD

Current Price

$47.81

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$12.29

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBH
MESO
Founded
1996
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
1.8B
IPO Year
2004
2005

Fundamental Metrics

Financial Performance
Metric
PBH
MESO
Price
$47.81
$12.29
Analyst Decision
Buy
Buy
Analyst Count
7
3
Target Price
★ $67.80
$37.00
AVG Volume (30 Days)
★ 496.7K
248.0K
Earning Date
11-05-2026
08-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.61
N/A
Revenue
★ $975,777,000.00
N/A
Revenue This Year
$17.03
$59.17
Revenue Next Year
$6.06
$59.00
P/E Ratio
$81.10
★ N/A
Revenue Growth
★ 36.77
N/A
52 Week Low
$42.62
$11.89
52 Week High
$71.07
$21.50

Technical Indicators

Market Signals
Indicator
PBH
MESO
Relative Strength Index (RSI) 48.82 34.52
Support Level $47.61 N/A
Resistance Level $50.00 $16.06
Average True Range (ATR) 1.41 0.42
MACD 0.18 -0.10
Stochastic Oscillator 46.39 15.12

Price Performance

Historical Comparison
PBH
MESO

About PBH Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: